Show simple item record

dc.contributor.advisorErnest Fraenkel.en_US
dc.contributor.authorPirhaji, Leilaen_US
dc.contributor.otherMassachusetts Institute of Technology. Department of Biological Engineering.en_US
dc.date.accessioned2016-09-13T19:14:47Z
dc.date.available2016-09-13T19:14:47Z
dc.date.copyright2016en_US
dc.date.issued2016en_US
dc.identifier.urihttp://hdl.handle.net/1721.1/104227
dc.descriptionThesis: Ph. D., Massachusetts Institute of Technology, Department of Biological Engineering, 2016.en_US
dc.descriptionCataloged from PDF version of thesis.en_US
dc.descriptionIncludes bibliographical references (pages 129-141).en_US
dc.description.abstractWhile technological advances have enabled measurements of thousands of molecules simultaneously, the data from each technology can only show a single-view of biological processes. Capturing a complete picture of these processes requires integrating data of different types, including clinical data, genomics, transcriptomics, proteomics and metabolomics. Here, we have demonstrated novel computational approaches for integrating a variety of biological data and used these methods to study Huntington's disease (HD). First, we established a computational approach for combining transcriptomics with qualitative, ordinal clinical information. Such data are available for a variety of diseases, but are rarely used in conjunction with molecular data. We adapted an ordinal regression model to analyze gene expression data from HD brains in conjunction with their grade of neuronal loss. This approach identified the SGPLl-encoded enzyme (SPL) as a potential therapeutic target for HD. Continuing our data-driven approach, we discovered the dysregulation of pathways associated with SPL and inferred molecular mechanisms by which SPL inhibition exerts protective effects. Then, we demonstrated a novel network-based, machine-learning algorithm for integrative analysis of untargeted metabolomic data. Metabolites are small molecules whose levels directly show cellular phenotypes. Despite their potential, the integrative analysis of metabolomic data has been limited because of challenges in metabolite identification. To address these challenges, we have developed a pioneering method for interpreting the large-scale metabolomic data in the context of other molecules such as proteins. We used our method to infer novel dysregulated pathways in a model of HD and experimentally verified our predictions. These two methods are extremely general and can be applied to a variety of diseases. As the costs of generating high-throughput data decrease, we anticipate that our approaches will have growing relevance to the discovery of therapeutic strategies for precision medicine.en_US
dc.description.statementofresponsibilityby Leila Pirhaji.en_US
dc.format.extent141 pagesen_US
dc.language.isoengen_US
dc.publisherMassachusetts Institute of Technologyen_US
dc.rightsMIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission.en_US
dc.rights.urihttp://dspace.mit.edu/handle/1721.1/7582en_US
dc.subjectBiological Engineering.en_US
dc.titleRevealing disease-associated pathways and components by systematic integration of large-scale biological dataen_US
dc.typeThesisen_US
dc.description.degreePh. D.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineering
dc.identifier.oclc958142368en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record